Mel Reichman's Drug Discovery Talk
Mel Reichman gave an outstanding presentation at Drexel on November 12, 2009. I think many of our faculty and students benefited from his unique perspective on high throughput drug discovery and the story of Vioxx from both chemistry and intellectual property considerations.
Unfortunately the resolution of the screen was changed during the presentation because the projector was not working properly. As a result some of the screen capture video got de-centered. I'm embedding the slides as well to see all the details.
Mel Reichman, senior investigator and director of the LIMR Chemical Genomics Center at the Lankenau Institute for Medical Research presents at the chemistry department at Drexel University on November 12, 2009. Introduction by Jean-Claude Bradley.
Modern drug discovery by high-throughput screening (HTS) begins with testing hundreds of thousands of compounds in biological assays. The confirmed hit rate for typical HTS is less than 0.5%; therefore, 99.5% of the costs of HTS are for generating null data. Orthogonal convolution of compound libraries (OCL) is 500% more efficient than present HTS practice. The OCL method combines 10 compounds per well. An advantage of this method is that each compound is represented twice in two separately arrayed pools. The potential for the approach to better enable academic centers of excellence to validate medicinally relevant biological targets is discussed.